Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04913285 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Pierre Fabre Medicament.
- Active
- Registry status
- Phase 1
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT04913285: Active Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Pierre Fabre Medicament.
NCT04913285 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by Pierre Fabre Medicament. The registered enrollment target is 400 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04913285, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by Pierre Fabre Medicament.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Primary Outcome
To determine the safety and tolerability of oral administration of KIN-2787 including dose-limiting toxicities (DLTs), and to identify the maximum tolerated dose (MTD) and/or the appropriate dose for further clinical investigation in Part B Dose Expansion.
Conditions Studied
Interventions
- DRUG KIN-2787
- DRUG KIN-2787 and binimetinib
Study Locations (20)
California
- The Angeles Clinic - Los Angeles
- UCLA - Los Angeles
- University of California San Diego, Moores Cancer Center - San Diego
- University of California San Francisco - San Francisco
- Stanford Cancer Center - Stanford
Florida
- Mayo Clinic - Florida - Jacksonville
- Sarah Cannon Research Institute - Florida Cancer Specialists - Orlando
New Jersey
- Atlantic Health - Morristown
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- NYU Langone - New York
- Memorial Sloan Kettering Cancer Center - New York
New South Wales
- Calvary Mater Hospital Newcastle - Waratah
- Melanoma Institute Australia - Wollstonecraft
Colorado
- Sarah Cannon Research Institute Denver - Denver
Minnesota
- Mayo Clinic - Rochester - Rochester
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-08-04 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 1 |
What the registry record for NCT04913285 still lists
NCT04913285 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (39% lower).
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which KIN-2787 is the first listed.
NCT04913285 names 20 study sites across 12 states, led by California, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04913285 about?
NCT04913285 is a clinical study titled "A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
What is the current status of trial NCT04913285?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 400 participants. The study started on 2021-08-04. Estimated completion is 2029-03-30.
What conditions does trial NCT04913285 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Solid Tumor, Adult.
What interventions are being tested in trial NCT04913285?
The interventions under investigation include: KIN-2787 (DRUG), KIN-2787 and binimetinib (DRUG).
Who is sponsoring clinical trial NCT04913285?
This trial is sponsored by Pierre Fabre Medicament, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04913285 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04913285's enrollment target sits among peer trials
400 98th of 454 higher than 353 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI